Contrasting Epstein-Barr virus-specific cytotoxic T cell responses to HLA A2-restricted epitopes in humans and HLA transgenic mice: implications for vaccine design

被引:19
作者
Bharadwaj, M [1 ]
Sherrit, M [1 ]
Khanna, R [1 ]
Moss, DJ [1 ]
机构
[1] Univ Queensland, Inst Med Res, Cooperat Res Ctr Vaccine Technol, Brisbane, Qld 4029, Australia
关键词
Epstein-Barr virus; CTL epitopes; vaccine design;
D O I
10.1016/S0264-410X(01)00085-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This study investigates the hierarchy of cytotoxic T cell (CTL) responses to twelve HLA AZ-restricted epitopes from the latent, lytic and structural proteins of Epstein-Barr virus (EBV) in acute infectious mononucleosis and in healthy seropositive donors and the relative immunogenecity of these epitopes in transgenic mice. Responses to the lytic epitope were uniformly strong in all healthy seropositive individuals and acute infectious mononucleosis donors while moderate or low responses were observed to the latent and structural epitopes. respectively in both groups studied. In contrast, when HLA A2/Kb transgenic mice were immunised with these peptide epitopes, CTL responses were observed to all epitopes with a maximal response to the epitopes within the structural proteins and low to moderate responses to the latent epitopes. This hierarchy of CTL responses in mice was also reflected in an MHC stabilisation analysis. These contrasting CTL responses in humans following natural infection compared to the immunogenicity of these epitopes and their ability to stabilise MHC mag; need to be considered when designing an EBV vaccine. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:3769 / 3777
页数:9
相关论文
共 28 条
[1]  
[Anonymous], 1996, Fields virology
[2]   Cost-efficient quantification of enzyme-linked immunospot [J].
Bharadmaj, M ;
Parsons, PG ;
Moss, DJ .
BIOTECHNIQUES, 2001, 30 (01) :36-+
[3]  
BISHOP CJ, 1985, CLIN EXP IMMUNOL, V60, P70
[4]   3 TRANSCRIPTIONALLY DISTINCT FORMS OF EPSTEIN-BARR-VIRUS LATENCY IN SOMATIC-CELL HYBRIDS - CELL PHENOTYPE DEPENDENCE OF VIRUS PROMOTER USAGE [J].
KERR, BM ;
LEAR, AL ;
ROWE, M ;
CROOMCARTER, D ;
YOUNG, LS ;
ROOKES, SM ;
GALLIMORE, PH ;
RICKINSON, AB .
VIROLOGY, 1992, 187 (01) :189-201
[5]  
Khanna R, 1999, J IMMUNOL, V162, P3063
[6]   Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation [J].
Khanna, R ;
Moss, DJ ;
Burrows, SR .
IMMUNOLOGICAL REVIEWS, 1999, 170 :49-64
[7]  
Khanna R, 1997, J IMMUNOL, V158, P3619
[8]   Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: Implications for viral persistence and tumor surveillance [J].
Khanna, R ;
Burrows, SR ;
SteigerwaldMullen, PM ;
Thomson, SA ;
Kurilla, MG ;
Moss, DJ .
VIROLOGY, 1995, 214 (02) :633-637
[9]  
Khanna R, 1998, EUR J IMMUNOL, V28, P451, DOI 10.1002/(SICI)1521-4141(199802)28:02<451::AID-IMMU451>3.0.CO
[10]  
2-U